| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/26/2006 | US7112612 N-alkylated GABA compounds, processes for their preparation and their use as medicaments |
| 09/26/2006 | US7112611 Antitumor, anticancer agents; respiratory system disorders; brain disorders |
| 09/26/2006 | US7112610 for treating restless leg syndrome; i.e. 3-Amino-5,8-dimethyl-nonanoic acid |
| 09/26/2006 | US7112609 Nutritional supplements |
| 09/26/2006 | US7112608 Hydroxyphenylundecane, a process for their production and their use |
| 09/26/2006 | US7112607 Antihypoxic agents, antiischamic agents, antiarrhythmia agents |
| 09/26/2006 | US7112606 Heterocyclic arylsulfonamidobenzylic compounds |
| 09/26/2006 | US7112605 cyclooxygenase-2 (COX-2) inhibitors; Non-steroidal anti-inflammatory drugs (NSAIDs) with side effect reduction; N-propyl-3-(4-methylsulfonylphenyl)-4-(4-chlorophenyl)-2,5-dihydropyrrole-2-one for example; rheumatoid arthritis |
| 09/26/2006 | US7112604 Process for the preparation of Atorvastatin and intermediates |
| 09/26/2006 | US7112603 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/26/2006 | US7112602 Methods of treating undesired angiogenesis with 2-methyl-EM-138 |
| 09/26/2006 | US7112601 Cycloalkyl heterocycles for treating hepatitis C virus |
| 09/26/2006 | US7112600 A therapeutic agent for treating hepatitis C, based on polymerase inhibitory activity |
| 09/26/2006 | US7112599 Oxazole compounds for the treatment of neurodegenerative disorders |
| 09/26/2006 | US7112598 κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative |
| 09/26/2006 | US7112597 5-(Substituted thiazolylethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/26/2006 | US7112596 Prenylation inhibitors and methods of their synthesis and use |
| 09/26/2006 | US7112595 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 09/26/2006 | US7112594 A N-phenyl-benzo(b)thiophene-carboxamide derivatives, as enzyme inhibitor of tyrosine kinase; antiproliferation of lymphocyte, treating autoimmune disease, rheumatic disease, as immunosuppressant, antiinflammatory agents |
| 09/26/2006 | US7112593 N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| 09/26/2006 | US7112592 Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
| 09/26/2006 | US7112591 Composition and method for humane euthanasia of animals |
| 09/26/2006 | US7112590 Anticoagulant for mammals |
| 09/26/2006 | US7112589 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
| 09/26/2006 | US7112588 Use of proteasome inhibitors to treat dry eye disorders |
| 09/26/2006 | US7112587 e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme |
| 09/26/2006 | US7112586 Substituted diamine derivatives useful as motilin antagonists |
| 09/26/2006 | US7112585 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms |
| 09/26/2006 | US7112584 Antiinflammatory agents; antiarthritic agents; antiallergens; antiinflammatory agents |
| 09/26/2006 | US7112583 Containing a benzodiazepine ring, e.g., (2(R)-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; treating Alzheimer's disease and Down's Syndrome |
| 09/26/2006 | US7112582 penicillins and oxapenicillins with a fused bicyclic N-heteroarymethylene group; 6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; antibiotic resistance is reduced when administered alone or with other B-lactam antibiotics |
| 09/26/2006 | US7112581 For therapy of cancer and infectious disease |
| 09/26/2006 | US7112580 3-nitrogen-6, 7-dioxygen steroids and uses related thereto |
| 09/26/2006 | US7112579 26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds |
| 09/26/2006 | US7112578 Methods and compositions for treatment of inflammatory disease |
| 09/26/2006 | US7112577 Pharmaceutically acceptable alendronate salts in amorphous form |
| 09/26/2006 | US7112576 Compositions and methods for cryopreservation of peripheral blood lymphocytes |
| 09/26/2006 | US7112575 Containing adenosine diphosphate and adenosine-2'-monophosphate, adenosine-3'-monophosphate, and/or adenosine-5'-monophosphate; protection from ionizing radiation, especially gamma-rays, x-rays, and beta-particles |
| 09/26/2006 | US7112574 found to be potent adenosine receptor agonists, in particular for the A2A receptor. |
| 09/26/2006 | US7112573 A picene ring containing compound substituted by a disaccharide and a trisaccharide group; anticarcinogenic agent |
| 09/26/2006 | US7112572 Multivalent metal salts of boronic acids |
| 09/26/2006 | US7112562 Insulin conjugates and methods of use thereof |
| 09/26/2006 | US7112430 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 09/26/2006 | US7112427 Protein comprising mitogenic kinase activity for identifying modulators of inflammation, apoptosis and cell proliferation; antiproliferative agents |
| 09/26/2006 | US7112414 Masp-2, a complement-fixing enzyme, and uses for it |
| 09/26/2006 | US7112340 Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| 09/26/2006 | US7112339 Compositions for controlled release of a biologically active agent, and the preparation thereof |
| 09/26/2006 | US7112338 Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 09/26/2006 | US7112337 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic |
| 09/26/2006 | US7112336 In an insoluble matrix, such as shellac, high molecular weight polyethylene glycol polyvinyl alcohol, lactic acid - glycolic acid copolymer or sugars. Particularly preferred compounds are: enrofloxacin, danofloxacin and sarafloxacin |
| 09/26/2006 | US7112324 CD 19×CD3 specific polypeptides and uses thereof |
| 09/26/2006 | US7112320 Solid wound healing formulations containing fibronectin |
| 09/26/2006 | CA2536501C Crystal forms of azithromycin |
| 09/26/2006 | CA2470201C Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| 09/26/2006 | CA2330686C Process for making 1,3-disubstituted-4-oxocyclic ureas |
| 09/26/2006 | CA2305762C Delayed total release gastrointestinal drug delivery system |
| 09/26/2006 | CA2288122C Neuropeptide y receptor antagonist |
| 09/26/2006 | CA2285383C Glycosaminoglycans having high antithrombotic activity |
| 09/26/2006 | CA2283464C Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 09/26/2006 | CA2279317C O-sulfated bacterial polysaccharides |
| 09/26/2006 | CA2278694C Sulfamide-metalloprotease inhibitors |
| 09/26/2006 | CA2254953C Therapies for chronic renal failure |
| 09/26/2006 | CA2254561C Method of producing dry thioctic acid |
| 09/26/2006 | CA2135312C Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy |
| 09/24/2006 | CA2539281A1 Methods for the treatment of insulin resistance and disease states characterized by insulin resistance |
| 09/24/2006 | CA2516364A1 Method of modulation |
| 09/21/2006 | WO2006099591A1 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| 09/21/2006 | WO2006099541A2 Therapeutic wound care product |
| 09/21/2006 | WO2006099539A1 Reg iv: a target for cancer diagnosis and therapy |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099479A2 Methods of treating cancer using ppar-gamma antagonists |
| 09/21/2006 | WO2006099474A1 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites |
| 09/21/2006 | WO2006099459A1 Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine |
| 09/21/2006 | WO2006099457A1 (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof |
| 09/21/2006 | WO2006099452A1 Anhydrous ziprasidone mesylate and a process for its preparation |
| 09/21/2006 | WO2006099433A1 Pure duloxetine hydrochloride |
| 09/21/2006 | WO2006099410A2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 09/21/2006 | WO2006099396A2 Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| 09/21/2006 | WO2006099385A2 Stabilized compositions of volatile alkylating agents and methods of using thereof |
| 09/21/2006 | WO2006099379A2 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
| 09/21/2006 | WO2006099374A1 Antiviral compositions and methods of use |
| 09/21/2006 | WO2006099353A1 Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| 09/21/2006 | WO2006099352A1 Novel isophthalates as beta-secretase inhibitors |
| 09/21/2006 | WO2006099351A2 Hydrocodone polymorphs |
| 09/21/2006 | WO2006099325A2 Methods of treating ear infections |
| 09/21/2006 | WO2006099314A1 Use of methylnaltrexone and related compounds to treat constipation in terminally ill patients |
| 09/21/2006 | WO2006099301A2 Apoptosis inhibitors |
| 09/21/2006 | WO2006099276A2 Biocompatible polymer compounds for medicinal formulations |
| 09/21/2006 | WO2006099275A2 Method of treating actinic keratosis |
| 09/21/2006 | WO2006099258A1 Tigecycline compositions and methods of preparation |
| 09/21/2006 | WO2006099244A1 Combination therapy for endothelial dysfunction, angina and diabetes |
| 09/21/2006 | WO2006099237A1 Nutritional preparations |
| 09/21/2006 | WO2006099231A1 Pyrimidine derivatives for treatment of hyperproliferative disorders |
| 09/21/2006 | WO2006099217A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 09/21/2006 | WO2006099204A1 Substituted 9-alkyladenines and the use thereof |
| 09/21/2006 | WO2006099196A1 Novel method |
| 09/21/2006 | WO2006099193A2 Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 09/21/2006 | WO2006099187A2 Benzoyl peroxide compositions and methods of use |
| 09/21/2006 | WO2006099167A1 Biphenyl compounds useful as muscarinic receptor antagonists |
| 09/21/2006 | WO2006099166A1 Crystalline forms of a biphenyl compound |